Encompass Health Q3 2026 earnings

EHC · 2026-10-28 16:26 AMC ET · 8-K on SEC

Revenue growth decelerated to 8.9% while Adjusted EBITDA accelerated to 15.5%, and the company raised full-year guidance across all metrics.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1,609.5M+8.9%+0.8%Ex. 99.1, Summary results
EPS (GAAP)$1.51+21.8%-0.04Ex. 99.1, Summary results
EPS (adjusted)$1.52+23.6%-0.03Ex. 99.1, Summary results
Net income$203.6M+16.6%-0.2Ex. 99.1, Summary results
Adj. EBITDA$346.6M+15.5%-0.4Ex. 99.1, Summary results
Adj. EBITDA margin21.6%+1.5 pp-0.1 ppEx. 99.1, Summary results

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $1,321.5M (+6.7% YoY)
  • One-offs in the quarter State regulatory change impact on noncontrolling interests ($1.5M); Gain on sale of Gamma Knife ($17.5M); Change in fair market value of marketable securities ($1.9M); Loss on early extinguishment of debt ($3.4M)
  • Effective tax rate 20.8% (prior-year 20.4%, year-to-date 20.2%)
  • Non-GAAP bridge Adds back depreciation and amortization, interest expense, stock-based compensation, loss on disposal or impairment, and non-recurring items like debt extinguishment and regulatory impacts.

KPIs

MetricActualPrior quarterPrior yearChange
Discharges69,60568,89565,839+5.7% YoY
Same-store discharge growth3%2.8%——
Net patient revenue per discharge$22,543$22,521$21,679+4% YoY

Guidance

MetricGuidePrior guideChange
Net operating revenue$6,450 to $6,500$6,410 to $6,490+$40 to $10
Adjusted EBITDA$1,395 to $1,415$1,365 to $1,395+$30 to $20
Adjusted earnings per share from continuing operations attributable to Encompass Health$6.23 to $6.37$6.02 to $6.25+$0.21 to $0.12

What drove it

  • Revenue story Revenue grew 8.9% year-over-year to $1.61 billion, driven by a 5.7% increase in discharges and a 4% increase in net patient revenue per discharge.
  • EPS story EPS growth was driven by higher revenue and a 1.5 percentage point expansion in Adjusted EBITDA margin, partially offset by share dilution.
  • One-off check State regulatory change impact on noncontrolling interests ($1.5M); Gain on sale of Gamma Knife ($17.5M); Change in fair market value of marketable securities ($1.9M); Loss on early extinguishment of debt ($3.4M).

The good

  • Adjusted EBITDA grew 15.5% year-over-year
  • Adjusted free cash flow grew 51.2% year-over-year to $263.4M
  • Company raised full-year guidance for revenue, Adjusted EBITDA, and adjusted EPS

The bad

  • Revenue growth decelerated from 9.6% in Q2 to 8.9% in Q3
  • Adjusted EBITDA margin contracted 0.1 percentage point quarter-over-quarter

The ugly

  • none

Open questions

  • The filing does not provide a breakdown of revenue by segment, product, or region.
  • The filing does not disclose the specific impact of the state regulatory change on noncontrolling interests.
Full release

Earnings: EHC — filed 2026-10-28

Encompass Health Corp (EHC) · Form 8-K, Item 2.02 · Filed · SEC filing

Encompass Health reports results for third quarter 2026

Increases full-year guidance

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the third quarter ended September 30, 2026.

Summary results

See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.

“We are very pleased with our performance for the third quarter, with revenue increasing 8.9% and Adjusted EBITDA growing 15.5%,” said Mark Tarr, President and Chief Executive Officer. “During the first nine months of 2026, we opened four hospitals totaling 189 beds and added 85 beds to existing hospitals, reflecting our commitment to meeting the growing demand for high-quality inpatient rehabilitation services. Our value proposition and disciplined operating strategy continue to be validated, and we remain highly optimistic about the long-term prospects of our business.”

2026 Guidance

The Company increased its full-year guidance as follows:

For considerations regarding the Company’s 2026 guidance, see the supplemental information posted on the Company’s website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.

Earnings conference call and webcast

The Company will host an investor conference call at 10:00 a.m. Eastern Time on Thursday, October 29, 2026 to discuss its results for the third quarter of 2026. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.

The conference call may be accessed by dialing 833 354-6854 and giving the conference ID EHCQ326. International callers should dial 785 838-9343 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected.

The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.

About Encompass Health

Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 179 hospitals in 39 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is recognized by

Newsweek as America’s Most Awarded Leader in Inpatient Rehabilitation and is ranked among

Fortune's

World’s Most Admired Companies™¹ and

Forbes’

America’s Best Companies. It is also recognized by Becker’s Healthcare and Modern Healthcare as a top healthcare employer. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.¹

From Fortune. © 2026 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World’s Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health.

Other information

The information in this press release is summarized and should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “September 2026 Form 10-Q”), when filed, as well as the Company’s Current Report on Form 8-K filed on October 28, 2026 (the “Q3 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its October 29, 2026 earnings call.

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q3 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q3 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company’s results computed in accordance with GAAP.

However, the following reasonably estimable GAAP measures for 2026 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:

• Interest expense and amortization of debt discounts and fees - approximately $130 million

• ... (truncated)debt-related items - approximately $10 million

The Q3 Earnings Form 8-K and, when filed, the September 2026 Form 10-Q can be found on the Company’s website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Encompass Health Corporation and Subsidiaries

Supplemental Information

Earnings Per Share

(1)

Income from continuing operations attributable to Encompass Health

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

* Adjusted EPS may not sum due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

* Reconciliation to GAAP provided on page 9

** Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

* Reconciliation to GAAP provided on page 9

** Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

* Reconciliation to GAAP provided on page 9

** Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

* Reconciliation to GAAP provided on page 9

** Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Income to Adjusted EBITDA

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

For the three months ended September 30, 2026, net cash used in investing activities was $241.6 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended September 30, 2026 was $153.7 million and resulted primarily from repurchases of common stock, distributions paid to noncontrolling interests of consolidated affiliates, net debt payments, and cash dividends paid on common stock.

For the three months ended September 30, 2025, net cash used in investing activities was $201.3 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended September 30, 2025 was $113.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, net debt payments, repurchases of common stock, and cash dividends paid on common stock.

For the nine months ended September 30, 2026 net cash used in investing activities was $627.3 million and resulted primarily from capital expenditures. Net cash used in financing activities during the nine months ended September 30, 2026 was $333.1 million and resulted primarily from repurchases of common stock, distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and taxes paid on behalf of employees for shares withheld partially offset by net debt borrowings.

For the nine months ended September 30, 2025, net cash used in investing activities was $525.2 million and resulted primarily from capital expenditures. Net cash used in financing activities during the nine months ended September 30, 2025 was $333.8 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock.

Encompass Health Corporation and Subsidiaries

Financial statements

Income Statement

Summary results (In Millions, Except Per Share Data)

Q3 2026Q3 2025Growth – DollarsGrowth – Percent
Net operating revenue1,609.51,477.51328.9
Income from continuing operations attributable to Encompass Health per diluted share1.511.240.2721.8
Adjusted earnings per share1.521.230.2923.6
Cash flows provided by operating activities362270.891.233.7
Adjusted EBITDA346.6300.146.515.5
Adjusted free cash flow263.4174.289.251.2
(Actual Amounts)Discharges69,60565,8395.7
(Actual Amounts)Same-store discharge growth3
(Actual Amounts)Net patient revenue per discharge22,54321,6794

Income Statement

The Company increased its full-year guidance as follows: (In Millions, Except Per Share Data)

Full-Year 2026 Guidance – Previous GuidanceFull-Year 2026 Guidance – Updated Guidance
Net operating revenue$6,410 to $6,490$6,450 to $6,500
Adjusted EBITDA$1,365 to $1,395$1,395 to $1,415
Adjusted earnings per share from continuing operations attributable to Encompass Health$6.02 to $6.25$6.23 to $6.37

Income Statement

Three Months Ended September 30, — (Unaudited) (In Millions, Except Per Share Data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net operating revenues1,609.51,477.54,793.54,390.6
Operating expenses:Salaries and benefits840.7784.82,479.12,314.8
Operating expenses:Other operating expenses245.2231.1742662.4
Operating expenses:Occupancy costs1514.944.944.5
Operating expenses:Supplies6564.6195.4189.9
Operating expenses:General and administrative expenses59.956.1180.7167.8
Operating expenses:Depreciation and amortization95.782.4273.4241.5
Operating expenses:Total operating expenses1,321.51,233.93,915.53,620.9
Operating expenses:Loss on early extinguishment of debt3.4
Operating expenses:Interest expense and amortization of debt discounts and fees32.230.896.893
Operating expenses:Other income-1.9-5.9-29.7-15.1
Operating expenses:Equity in net income of nonconsolidated affiliates-0.1-1.2-0.6-3.5
Operating expenses:Income from continuing operations before income tax expense257.8219.9808.1695.3
Operating expenses:Provision for income tax expense53.444.9163.4137.5
Operating expenses:Income from continuing operations204.4175644.7557.8
Operating expenses:(Loss) income from discontinued operations, net of tax-0.8-0.414.5-1.8
Operating expenses:Net income203.6174.6659.2556
Operating expenses:Less: Net income attributable to noncontrolling interests-53.7-48.1-160.9-135.9
Operating expenses:Net income attributable to Encompass Health149.9126.5498.3420.1
Weighted average common shares outstanding:Basic98.3100.598.8100.5
Weighted average common shares outstanding:Diluted99.7102.3100.2102.3
Basic earnings per share attributable to Encompass Health common shareholders:Continuing operations1.531.264.884.19
Basic earnings per share attributable to Encompass Health common shareholders:Discontinued operations-0.010.15-0.02
Basic earnings per share attributable to Encompass Health common shareholders:Net income1.521.265.034.17
Diluted earnings per share attributable to Encompass Health common shareholders:Continuing operations1.511.244.834.13
Diluted earnings per share attributable to Encompass Health common shareholders:Discontinued operations-0.010.14-0.02
Diluted earnings per share attributable to Encompass Health common shareholders:Net income1.51.244.974.11
Amounts attributable to Encompass Health common shareholders:Income from continuing operations150.7126.9483.8421.9
Amounts attributable to Encompass Health common shareholders:(Loss) income from discontinued operations, net of tax-0.8-0.414.5-1.8
Amounts attributable to Encompass Health common shareholders:Net income attributable to Encompass Health149.9126.5498.3420.1

Income Statement

Three Months Ended September 30, — Earnings Per Share (In Millions, Except Per Share Data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Adjusted EBITDA346.6300.11,043.4932.3
Depreciation and amortization-95.7-82.4-273.4-241.5
Interest expense and amortization of debt discounts and fees-32.2-30.8-96.8-93
Stock-based compensation-15-14.3-40.3-38.1
Loss on disposal or impairment of assets-0.8-1.9-3.2-2.4
202.9170.7629.7557.3
Items not indicative of ongoing operating performance:Loss on early extinguishment of debt-3.4
Items not indicative of ongoing operating performance:State regulatory change impact on noncontrolling interests1.51.5
Items not indicative of ongoing operating performance:Change in fair market value of marketable securities-0.31.11.92.1
Items not indicative of ongoing operating performance:Gain on sale of Gamma Knife17.5
Items not indicative of ongoing operating performance:Pre-tax income204.1171.8647.2559.4
Items not indicative of ongoing operating performance:Income tax expense-53.4-44.9-163.4-137.5
Items not indicative of ongoing operating performance:Income from continuing operations (1)150.7126.9483.8421.9
Items not indicative of ongoing operating performance:Basic shares98.3100.598.8100.5

Income Statement

Three Months Ended September 30, — Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net cash provided by operating activities362270.8957.7829.6
Interest expense and amortization of debt discounts and fees32.230.896.893
(Loss) gain on investments, excluding impairments-0.8321.86.2
Equity in net income of nonconsolidated affiliates0.11.20.63.5
Net income attributable to noncontrolling interests in continuing operations-53.7-48.1-160.9-135.9
Amortization of debt-related items-2.1-2.4-6.7-7.2
Distributions from nonconsolidated affiliates-0.1-0.3-1.4
Current portion of income tax expense57.247161.8134.3
Change in assets and liabilities-48.1-1.812.89.6
Cash used in (provided by) operating activities of discontinued operations1.10.6-19.22.5
State regulatory change impact on noncontrolling interests-1.5-1.5
Change in fair market value of marketable securities0.3-1.1-1.9-2.1
Gain on sale of Gamma Knife-17.5
Other0.1-0.10.2
Adjusted EBITDA346.6300.11,043.4932.3

Income Statement

For the Three Months Ended September 30, 2026 — Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

For the Three Months Ended September 30, 2026 – As ReportedFor the Three Months Ended September 30, 2026 – Adjustments – State Regulatory Change ImpactChange in Fair Market Value of Marketable SecuritiesAs Adjusted
Adjusted EBITDA*346.6346.6
Depreciation and amortization-95.72.9-92.8
Interest expense and amortization of debt discounts and fees-32.2-32.2
Stock-based compensation-15-15
Loss on disposal or impairment of assets-0.8-0.8
State regulatory change impact on noncontrolling interests1.5-1.5
Change in fair market value of marketable securities-0.30.3
Income from continuing operations before income tax expense204.11.40.3205.8
Provision for income tax expense-53.4-0.4-0.1-53.9
Income from continuing operations attributable to Encompass Health150.710.2151.9
Diluted earnings per share from continuing operations**1.510.011.52
Diluted shares used in calculation99.7

Income Statement

For the Three Months Ended September 30, 2025 — Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

For the Three Months Ended September 30, 2025 – As ReportedFor the Three Months Ended September 30, 2025 – Adjustments – Income Tax AdjustmentsAdjustments – Change in Fair Market Value of Marketable SecuritiesAs Adjusted
Adjusted EBITDA*300.1300.1
Depreciation and amortization-82.4-82.4
Interest expense and amortization of debt discounts and fees-30.8-30.8
Stock-based compensation-14.3-14.3
Loss on disposal or impairment of assets-1.9-1.9
Change in fair market value of marketable securities1.1-1.1
Income from continuing operations before income tax expense171.8-1.1170.7
Provision for income tax expense-44.9-0.20.3-44.8
Income from continuing operations attributable to Encompass Health126.9-0.2-0.8125.9
Diluted earnings per share from continuing operations**1.24-0.011.23
Diluted shares used in calculation102.3

Income Statement

For the Nine Months Ended September 30, 2026 — Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

For the Nine Months Ended September 30, 2026 – As ReportedFor the Nine Months Ended September 30, 2026 – Adjustments – State Regulatory Change ImpactFor the Nine Months Ended September 30, 2026 – Adjustments – Loss on Early Exting. of DebtFor the Nine Months Ended September 30, 2026 – Adjustments – Income Tax AdjustmentsFor the Nine Months Ended September 30, 2026 – Adjustments – Change in Fair Market Value of Marketable SecuritiesFor the Nine Months Ended September 30, 2026 – Adjustments – Gain on Sale of Gamma KnifeFor the Nine Months Ended September 30, 2026 – As Adjusted
Adjusted EBITDA*1,043.41,043.4
Depreciation and amortization-273.42.9-270.5
Interest expense and amortization of debt discounts and fees-96.8-96.8
Stock-based compensation-40.3-40.3
Loss on disposal or impairment of assets-3.2-3.2
Loss on early extinguishment of debt-3.43.4
State regulatory change impact on noncontrolling interests1.5-1.5
Change in fair market value of marketable securities1.9-1.9
Gain on sale of Gamma Knife17.5-17.5
Income from continuing operations before income tax expense647.21.43.4-1.9-17.5632.6
Provision for income tax expense-163.4-0.4-0.9-5.20.54.5-164.9
Income from continuing operations attributable to Encompass Health483.812.5-5.2-1.4-13467.7
Diluted earnings per share from continuing operations**4.830.010.02-0.05-0.01-0.134.67

Income Statement

For the Nine Months Ended September 30, 2025 — Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

For the Nine Months Ended September 30, 2025 – As ReportedFor the Nine Months Ended September 30, 2025 – Adjustments – Income Tax AdjustmentsAdjustments – Change in Fair Market Value of Marketable SecuritiesAs Adjusted
Adjusted EBITDA*932.3932.3
Depreciation and amortization-241.5-241.5
Interest expense and amortization of debt discounts and fees-93-93
Stock-based compensation-38.1-38.1
Loss on disposal or impairment of assets-2.4-2.4
Change in fair market value of marketable securities2.1-2.1
Income from continuing operations before income tax expense559.4-2.1557.3
Provision for income tax expense-137.5-11.80.6-148.7
Income from continuing operations attributable to Encompass Health421.9-11.8-1.5408.6
Diluted earnings per share from continuing operations**4.13-0.12-0.013.99
Diluted shares used in calculation102.3

Income Statement

Three Months Ended September 30, — Reconciliation of Net Income to Adjusted EBITDA (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income203.6174.6659.2556
Loss (income) from discontinued operations, net of tax, attributable to Encompass Health0.80.4-14.51.8
Net income attributable to noncontrolling interests included in continuing operations-53.7-48.1-160.9-135.9
Provision for income tax expense53.444.9163.4137.5
Interest expense and amortization of debt discounts and fees32.230.896.893
Depreciation and amortization95.782.4273.4241.5
Loss on early extinguishment of debt3.4
Loss on disposal or impairment of assets0.81.93.22.4
Stock-based compensation1514.340.338.1
State regulatory change impact on noncontrolling interests-1.5-1.5
Change in fair market value of marketable securities0.3-1.1-1.9-2.1
Gain on sale of Gamma Knife-17.5
Adjusted EBITDA346.6300.11,043.4932.3

Balance Sheet

September 30, 2026 — (Unaudited) (in millions)

September 30, 2026December 31, 2025
Current assets:Cash and cash equivalents76.272.2
Current assets:Restricted cash2430.7
Current assets:Accounts receivable712619.2
Current assets:Other current assets200.8183.8
Current assets:Total current assets1,013905.9
Current assets:Property and equipment, net4,477.64,101.6
Current assets:Operating lease right-of-use assets194.5212.6
Current assets:Goodwill1,323.51,317.6
Current assets:Intangible assets, net301.5308.3
Current assets:Other long-term assets256.4243.7
Current assets:Total assets7,566.57,089.7
Current liabilities:Current portion of long-term debt47.843.6
Current liabilities:Current operating lease liabilities2826.5
Current liabilities:Accounts payable231.4178.2
Current liabilities:Accrued expenses and other current liabilities620.2588.1
Current liabilities:Total current liabilities927.4836.4
Current liabilities:Long-term debt, net of current portion2,551.32,447.2
Current liabilities:Long-term operating lease liabilities176.3196.6
Current liabilities:Deferred income tax liabilities127.5126.8
Current liabilities:Other long-term liabilities222.8206.9
Current liabilities:Total liabilities4,005.33,813.9
Commitments and contingenciesRedeemable noncontrolling interests58.658.3
Shareholders’ equity:Encompass Health shareholders’ equity2,681.22,438.2
Shareholders’ equity:Noncontrolling interests821.4779.3
Shareholders’ equity:Total shareholders’ equity3,502.63,217.5
Shareholders’ equity:Total liabilities and shareholders’ equity7,566.57,089.7

Cash Flow

Nine Months Ended September 30, — (Unaudited) (in millions)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:Net income659.2556
Cash flows from operating activities:(Income) loss from discontinued operations, net of tax-14.51.8
Adjustments to reconcile net income to net cash provided by operating activities—Depreciation and amortization273.4241.5
Adjustments to reconcile net income to net cash provided by operating activities—Loss on early extinguishment of debt3.4
Adjustments to reconcile net income to net cash provided by operating activities—Stock-based compensation40.338.1
Adjustments to reconcile net income to net cash provided by operating activities—Deferred tax expense1.63.2
Adjustments to reconcile net income to net cash provided by operating activities—Gain on investments-21.8-6.1
Adjustments to reconcile net income to net cash provided by operating activities—Other, net9.77.2
Change in assets and liabilities, net of acquisitions—Accounts receivable-89.5-18.8
Change in assets and liabilities, net of acquisitions—Other assets-20.8-19.5
Change in assets and liabilities, net of acquisitions—Accounts payable43.5-32.7
Change in assets and liabilities, net of acquisitions—Accrued payroll13.66.4
Change in assets and liabilities, net of acquisitions—Accrued interest payable-5.7-15.8
Change in assets and liabilities, net of acquisitions—Other liabilities46.170.8
Change in assets and liabilities, net of acquisitions—Net cash provided by (used in) operating activities of discontinued operations19.2-2.5

Cash Flow

Three Months Ended September 30, — Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net cash provided by operating activities362270.8957.7829.6
Impact of discontinued operations1.10.6-19.22.5
Net cash provided by operating activities of continuing operations363.1271.4938.5832.1
Capital expenditures for maintenance-56-61.4-166-140.5
Distributions paid to noncontrolling interests of consolidated affiliates-43.7-36.1-141.8-109.4
Items not indicative of ongoing operating performance:Transaction costs and related liabilities0.33.50.3
Items not indicative of ongoing operating performance:Adjusted free cash flow263.4174.2634.2582.5

Forward-Looking Statements

Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the business, strategy, outlook, growth targets and guidance considerations, dividend strategies, effective income tax rates, cost trends, legislative and regulatory developments or their impacts, financial guidance, ability to return value to shareholders, projected capital expenditures, acquisition opportunities, development projects, addressable market size, other balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, possible reductions or other changes in Medicaid reimbursement, including Medicaid directed and supplemental payment programs and Medicaid waiver programs, which may decrease our revenues and increase our provider tax expenses; infectious disease outbreak, including the speed, depth, geographic reach and duration of its spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health’s services, including based on any downturns in the economy and consumer confidence in patient care; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' or partners’ information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes, including in connection with the CMS inpatient rehabilitation review choice demonstration project; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis, including as part of the review choice demonstration; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing such as the transforming episode accountability model and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by infectious disease outbreaks, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any instability or uncertainty related to trade war, armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in

Encompass Health Corporation and Subsidiaries

Forward-Looking Statements the cost of, or the decrease in the availability of, construction materials and necessary supplies, including as a result of tariffs and import restrictions; the increase in the costs of defending and insuring against alleged professional liability claims, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2025 and Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, when filed.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Encompass Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.